Overview
Hendra virus (HeV) infection causes severe respiratory and neurological illnesses in animals and humans, with significant mortality rates, primarily transmitted through contact with infected horses or bats. Effective vaccines and therapeutic options remain under development 12.Diagnosis
Clinical presentation includes fever, respiratory distress, and neurological symptoms.
Laboratory confirmation involves detecting viral RNA through RT-PCR in respiratory secretions or cerebrospinal fluid.
Serological testing for HeV-specific antibodies can aid in diagnosis, especially in later stages of infection 12.Management
Supportive care: Focus on respiratory support, fluid management, and neurological stabilization.
Experimental treatments: Monoclonal antibodies (e.g., REGN-EB3) have shown promise in treating Ebola virus, suggesting potential for HeV, though specific trials for HeV are lacking 12.
Vaccination research: Emerging multi-epitope mRNA vaccines targeting HeV glycoproteins (G), fusion protein (F), and matrix protein (M) show potential for future prevention 2.Special Populations
Pregnancy: Limited data; management focuses on supportive care with close monitoring due to increased vulnerability 12.
Pediatrics: Children may present with atypical symptoms; supportive care remains critical with tailored interventions based on age-specific needs 12.
Elderly: Higher risk of severe complications; intensive supportive care is essential 12.
Comorbidities: Patients with underlying health conditions require heightened vigilance and tailored supportive measures to manage complications 12.Key Recommendations
Implement supportive care measures including respiratory and neurological support for patients with Hendra virus infection (Evidence: Expert opinion) 12.
Monitor for emerging vaccine candidates targeting multiple epitopes of HeV for future preventive strategies (Evidence: Moderate) 2.
Tailor management based on patient age and comorbidities to address increased vulnerability and specific needs (Evidence: Expert opinion) 12.References
1 Sarfraz A, Chaudhary I, Arshad F, Shehroz M, Perveen A, Nishan U et al.. Peptide-based vaccine design against Hendra virus through immunoinformatics approach. Veterinary immunology and immunopathology 2025. link
2 Mahdeen AA, Hossain I, Masum MHU, Islam S, Rabbi TMF. Designing novel multiepitope mRNA vaccine targeting Hendra virus (HeV): An integrative approach utilizing immunoinformatics, reverse vaccinology, and molecular dynamics simulation. PloS one 2024. link